Celadon Pharmaceuticals (LSE:CEL) EV-to-Revenue : 776.75 (As of May. 22, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Celadon Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Celadon Pharmaceuticals's enterprise value is €67.58 Mil. Celadon Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €0.09 Mil. Therefore, Celadon Pharmaceuticals's EV-to-Revenue for today is 776.75.

The historical rank and industry rank for Celadon Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

LSE:CEL' s EV-to-Revenue Range Over the Past 10 Years
Min: 644.05 Med: 757.87 Max: 864.59
Current: 776.74

During the past 5 years, the highest EV-to-Revenue of Celadon Pharmaceuticals was 864.59. The lowest was 644.05. And the median was 757.87.

LSE:CEL's EV-to-Revenue is ranked worse than
99.03% of 1026 companies
in the Drug Manufacturers industry
Industry Median: 2.335 vs LSE:CEL: 776.74

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-22), Celadon Pharmaceuticals's stock price is €0.97. Celadon Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00. Therefore, Celadon Pharmaceuticals's PS Ratio for today is 970.00.

Celadon Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Celadon Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celadon Pharmaceuticals EV-to-Revenue Chart

Celadon Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

1,068.44

895.19

Celadon Pharmaceuticals Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial			-	-	1,068.44	-	895.19

Competitive Comparison of Celadon Pharmaceuticals's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Celadon Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celadon Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celadon Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Celadon Pharmaceuticals's EV-to-Revenue falls into.

Celadon Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Celadon Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	67.577	/	0.087
	=	776.75

Celadon Pharmaceuticals's current Enterprise Value is €67.58 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Celadon Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €0.09 Mil.

Celadon Pharmaceuticals (LSE:CEL) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Celadon Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.97	/	0.001
	=	970.00

Celadon Pharmaceuticals's share price for today is €0.97.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was €0.00.

Celadon Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Celadon Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Celadon Pharmaceuticals (LSE:CEL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

32-33 Cowcross Street, London, GBR, EC1M 6DF

Website

https://www.celadonpharma.co.uk

Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis.

Celadon Pharmaceuticals (LSE:CEL) Headlines

No Headlines